Figure 2.

The conventional imaging agent Optimark results in tumor enhancement of orthotopic glioma tumors in mice at 0.1- and 0.2-mmol/kg. Representative bright-field images of athymic mice bearing Gli36Δ5 glioma tumors that received 0.1- or 0.2-mmol/kg Optimark. T2-weighted high-resolution images show the tumor mass and are co-registered with their corresponding T1-weighted images below and quantitative maps in Figure 3, Figure 5. T1-weighted images of orthotopic Gli36Δ5 glioma tumors at baseline (before injection of contrast agents) and at time of maximum contrast (5 minutes) following intravenous administration are shown.